AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

10.10.17	AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology (PR Newswire)
09.10.17	AbbVie to Host Third-Quarter 2017 Earnings Conference Call (PR Newswire)
03.10.17	Bryan Benjamin Joins The Conference Board of Canada as Vice-President, Organizational Performance (PR Newswire)
02.10.17	Metro Supply Chain Group Appoints New U.S. Business Lead (PR Newswire)
30.09.17	Concours de l'Ordre national du mérite agricole - Le ministre Laurent Lessard rend hommage aux artisans du secteur agricole québécois (PR Newswire)
28.09.17	AbbVie Inc. -- Moody's: AbbVie's Humira patent settlement reduces uncertainty (Moodys)
28.09.17	Amgen, AbbVie Settle Litigation Regarding AMGEVITA - Quick Facts (RTTNews)
28.09.17	AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen (PR Newswire)
27.09.17	AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan (PR Newswire)
22.09.17	AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors (PR Newswire)
21.09.17	Soleil Capital Corp. Announces Qualifying Transaction (PR Newswire)
20.09.17	Nominations du Conseil des ministres (PR Newswire)
18.09.17	Deck Design 101 (PR Newswire)
18.09.17	AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with... (PR Newswire)
13.09.17	Breakfast Technical Briefing on Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson (PR Newswire)
12.09.17	Keep Close Watch On ALDX Today, ABBV Just Hit Another High, Fennec Uplisted (RTTNews)
11.09.17	Little-Known Biotech Breakthrough Could Save Millions Of Lives (PR Newswire)
11.09.17	AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis (PR Newswire)
08.09.17	AbbVie Declares Quarterly Dividend (PR Newswire)
08.09.17	Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High (RTTNews)
07.09.17	AbbVie Leads Biotechnology Industry on Dow Jones Sustainability Index for Second Consecutive Year (PR Newswire)
07.09.17	AbbVie'Upadacitinib Meets Primary Endpoint In Phase2b Study In Atopic Dermatitis (RTTNews)
07.09.17	AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis (PR Newswire)
07.09.17	AbbVie to Present at the Morgan Stanley 15th Annual Global Health Care Conference (PR Newswire)
07.09.17	New Drugs Approved In August (RTTNews)
06.09.17	AbbVie Submits NDA To FDA For Investigational Oral Treatment Elagolix (RTTNews)
06.09.17	AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain (PR Newswire)
04.09.17	Inventiva, AbbVie Extend Deal To Develop Orally Available ROR? Inverse Agonists (RTTNews)
29.08.17	AT&T Pledges $350,000 to Aid Communities Impacted by Hurricane Harvey (PR Newswire)
29.08.17	Biotech Stocks Facing FDA Decision In September (RTTNews)
22.08.17	Global Smart Wearable Gloves Market to Grow at a CAGR of 15.2% by 2021: Key Vendors are Blue Infusion Technology, Neofect & ProGlove (PR Newswire)
10.08.17	Technical Snapshots for These Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson (PR Newswire)
04.08.17	DVAX Plunges On Delay In Approval, FDA Nod For ABBV's HCV Drug, ABIO On Radar (RTTNews)
04.08.17	FDA Approves AbbVie's Mavyret For Hepatitis C (RTTNews)
03.08.17	AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks (PR Newswire)
02.08.17	U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) -- A Serious, Potentially Life-Threatening Condition --... (PR Newswire)
31.07.17	Biotech Stocks Facing FDA Decision In August (RTTNews)
31.07.17	DVAX Surges On FDA Panel Vote, CYTR On Watch, EU Approves New HCV Drugs (RTTNews)
28.07.17	European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) (PR Newswire)
28.07.17	European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) (PR Newswire)
28.07.17	AbbVie Reports Second-Quarter 2017 Financial Results (PR Newswire)
25.07.17	AbbVie Ordered To Pay $150 Mln In AndroGel Lawsuit (RTTNews)
24.07.17	One Step Closer To EU Approval... (RTTNews)
21.07.17	AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis (PR Newswire)
19.07.17	Industry Leaders Riding High as Marijuana Demand Outpaces Supply (PR Newswire)
17.07.17	Billionaires Bet Big On Canada's Newest $22 Billion Market (PR Newswire)
10.07.17	AbbVie to Host Second-Quarter 2017 Earnings Conference Call (PR Newswire)
26.06.17	Breakfast Technical Briefing on Drug Makers Stocks -- Pfizer, Merck, AbbVie, and Johnson & Johnson (PR Newswire)
23.06.17	AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) (PR Newswire)
23.06.17	AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’346.50	0.86 %	K V
CieFinRichemont	165.35	0.79 %	K V
Alcon	78.32	0.44 %	K V
Sonova Hldg	305.40	0.39 %	K V
Swisscom	514.50	0.39 %	K V
Roche Hldg G	265.70	-0.45 %	K V
ABB	50.66	-0.63 %	K V
Holcim	86.72	-0.80 %	K V
Geberit	502.20	-0.83 %	K V
Sika	224.20	-1.32 %	K V

mehr

15.01.25		Pluszeichen in New York: S&P 500 zum Ende des Mittwochshandels in der Gewinnzone
15.01.25		Börse New York in Grün: S&P 500 legt zu
15.01.25		Freundlicher Handel in New York: So performt der S&P 500 am Mittag
15.01.25		Aufschläge in New York: S&P 500 zum Start stärker
11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

15.01.25

Pluszeichen in New York: S&P 500 zum Ende des Mittwochshandels in der Gewinnzone

15.01.25

Börse New York in Grün: S&P 500 legt zu

15.01.25

Freundlicher Handel in New York: So performt der S&P 500 am Mittag

15.01.25

Aufschläge in New York: S&P 500 zum Start stärker

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus